Aumolertinib plus bevacizumab for untreated advanced NSCLC with EGFR sensitive mutation
{{output}}
Background: Aumolertinib is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with proven efficacy and safety for untreated non-small-cell lung cancer (NSCLC) patients with EGFR sensit... ...
